A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
Jiangsu Nutai Biologics Co., Ltd
Jiangsu Nutai Biologics Co., Ltd
Pfizer
Helsinn Healthcare SA
Helsinn Healthcare SA
Pfizer
Pfizer
CSL Behring
Chugai Pharma France
Helsinn Therapeutics (U.S.), Inc
Helsinn Therapeutics (U.S.), Inc
Helsinn Therapeutics (U.S.), Inc
Smartfish AS
Novartis
Akamis Bio
GTx
Helsinn Therapeutics (U.S.), Inc
Vicus Therapeutics
Acacia Pharma Ltd
Centocor, Inc.